ArticleFrontiers in pharmacology2025
Adherence and persistence with istradefylline treatment in patients with Parkinson's disease in the United States.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication adherence and persistence are associated with better outcomes for patients with Parkinson's disease. Objectives: To evaluate 12-month adherence and persistence with istradefylline and identify factors associated with persistence among patients. Methods: A retrospective cohort study was conducted using IQVIA longitudinal prescription (LRx) and medical (Dx) claims data. Adult patients initiating istradefylline between 2019 and 2022 with ≥1 LRx and ≥1 Dx claim every 6 months over 12-month baseline and follow-up periods were included. Adherence was measured by the proportion of days covered (PDC) and medication possession ratio (MPR). Persistence was measured by the duration of prescription fills, allowing for a ≤60-day gap. Multivariate logistic regression was used to evaluate factors associated with 12-month persistence. Results: Among 2,045 patients, 76.0% were covered by Medicare Advantage and 23.9% were commercially insured. Over 12 months of follow-up, median adherence (both PDC and MPR) was 74.0% and median persistence was 276 days. In a subgroup analysis, median adherence and persistence were significantly greater in patients with Medicare Advantage Conclusion: Patients initiating istradefylline at 40 mg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.